<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">Infection with covid 19 causes inflammation in lungs which disconnect the hemoglobulin to carry required oxygen for the body. Chloroquine is the anti-inflammatory agent which even help to treat lupus erythematosus and rheumatoid arthritis at the effective dose of 500Â mg [
 <xref ref-type="bibr" rid="CR16">16</xref>]. It has broad-spectrum antiviral activities which interferes with the glycosylation of cellular receptors by increasing endosomal pH a major requirement for the fusion of virus and cell [
 <xref ref-type="bibr" rid="CR20">20</xref>]. The advantage of using chloroquine is that it is effective at both entries and at the post-entry stage of infection [
 <xref ref-type="bibr" rid="CR21">21</xref>] and even act as immune modulator increases the potentiality as antiviral effect in vivo. It is bioavailable to whole body including lungs after administration. Presenting these findings in a conference on February 15, 2020 to the experts from government and regulatory authorities and organizers of clinical trials approved the use of chloroquine phosphate against COVID-19 [
 <xref ref-type="bibr" rid="CR10">10</xref>].
</p>
